David Ge

Dr. Ge is CEO & President of Apostle. Previously, he was President of BioSciKin Co. and Simcere Diagnostics Co., part of Simcere Pharmaceutical Group (HKG: 2096). Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences (NASDAQ: GILD), where he founded the bioinformatics group and provided the strategic input to the bioinformatics infrastructure and process. At Gilead, Dr. Ge and his group led the phylogenomic analytical support for the critical regulatory approval of Sovaldi®, a world-leading medication used to treat hepatitis C viral (HCV) infection. In 2014 and 2015, Dr. Ge was invited to the U.S. NIH National Human Genome Research Institute Special Emphasis Panel. Prior to Gilead, he was Assistant Professor of Biostatistics and Bioinformatics and Assistant Professor in Medicine at Duke University School of Medicine. At Duke, Dr. Ge's work in discovering the IL28B genetic variants associated with the clinical treatment responses to HCV infection, published in Nature in 2009, has received over 4,000 times of citations to date. He received his Ph.D. of Biostatistics and Genetic Epidemiology in 2004 from Peking Union Medical College and Chinese Academy of Medical Sciences, among the most selective medical colleges in China, and received his postdoctoral training at Duke University between 2006 and 2008.